Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Promising Pipeline | Protagonist's rusfertide and icotrokinra show potential in polycythemia vera and inflammatory bowel diseases, with projected peak sales in billions |
Financial Strength | $698M cash reserves provide runway through 2028, supporting aggressive development of early-stage assets despite current operating losses |
Competitive Edge | PN-881, a highly potent IL-17 antagonist, could revolutionize psoriasis treatment, potentially outperforming existing antibody-based therapies |
Market Outlook | Analysts set price targets ranging from $50 to $80, reflecting optimism about Protagonist's pipeline and market potential in multiple therapeutic areas |
Metrics to compare | PTGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTGXPeersSector | |
---|---|---|---|---|
P/E Ratio | 59.4x | −1.7x | −0.5x | |
PEG Ratio | −0.87 | −0.07 | 0.00 | |
Price/Book | 4.8x | 2.2x | 2.6x | |
Price / LTM Sales | 16.1x | 38.1x | 3.3x | |
Upside (Analyst Target) | 29.9% | 303.2% | 43.5% | |
Fair Value Upside | Unlock | 20.0% | 6.9% | Unlock |